ALNYLAM PHARMS INC

Active trials

• phase3TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathyrecruitingn=1,750
• phase2A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMactive not recruitingn=105
• phase1A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOADrecruitingn=60
• phase2A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathyrecruitingn=200
• phase2A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)active not recruitingn=89
• phase1A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinomarecruitingn=158
• phase3Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Diseaserecruitingn=11,000
• phase1A Study to Evaluate ALN-5288 in Patients With Alzheimer's Diseaserecruitingn=50